Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection.

Gay CL, Kuruc JD, Falcinelli SD, Warren JA, Reifeis SA, Kirchherr JL, James KS, Dewey MG, Helms A, Allard B, Stuelke E, Gamble A, Plachco A, Gorelick RJ, Eron JJ, Hudgens M, Garrido C, Goonetilleke N, DeBenedette MA, Tcherepanova IY, Nicolette CA, Archin NM, Margolis DM.

Sci Rep. 2020 Mar 20;10(1):5134. doi: 10.1038/s41598-020-61878-3.

2.

Dynamic Shifts in the HIV Proviral Landscape During Long Term Combination Antiretroviral Therapy: Implications for Persistence and Control of HIV Infections.

Anderson EM, Simonetti FR, Gorelick RJ, Hill S, Gouzoulis MA, Bell J, Rehm C, Pérez L, Boritz E, Wu X, Wells D, Hughes SH, Rao V, Coffin JM, Kearney MF, Maldarelli F.

Viruses. 2020 Jan 25;12(2). pii: E136. doi: 10.3390/v12020136.

3.

White Matter Abnormalities Linked to Interferon, Stress Response, and Energy Metabolism Gene Expression Changes in Older HIV-Positive Patients on Antiretroviral Therapy.

Solomon IH, Chettimada S, Misra V, Lorenz DR, Gorelick RJ, Gelman BB, Morgello S, Gabuzda D.

Mol Neurobiol. 2020 Feb;57(2):1115-1130. doi: 10.1007/s12035-019-01795-3. Epub 2019 Nov 5.

PMID:
31691183
4.

Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma.

Reid EG, Suazo A, Lensing SY, Dittmer DP, Ambinder RF, Maldarelli F, Gorelick RJ, Aboulafia D, Mitsuyasu R, Dickson MA, Wachsman W; AIDS Malignancy Consortium (AMC).

Clin Cancer Res. 2020 Feb 1;26(3):558-565. doi: 10.1158/1078-0432.CCR-19-1044. Epub 2019 Oct 17.

PMID:
31624104
5.

Evaluating the Intactness of Persistent Viral Genomes in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Initiating Antiretroviral Therapy within One Year of Infection.

Long S, Fennessey CM, Newman L, Reid C, O'Brien SP, Li Y, Del Prete GQ, Lifson JD, Gorelick RJ, Keele BF.

J Virol. 2019 Dec 12;94(1). pii: e01308-19. doi: 10.1128/JVI.01308-19. Print 2019 Dec 12.

PMID:
31597776
6.

A Phase I, Randomized, Controlled Clinical Study of CC-11050 in People Living With HIV With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE).

Boulougoura A, Gabriel E, Laidlaw E, Khetani V, Arakawa K, Higgins J, Rupert A, Gorelick RJ, Lumbard K, Pau A, Poole A, Kibiy A, Kumar P, Sereti I.

Open Forum Infect Dis. 2019 Jun 3;6(6):ofz246. doi: 10.1093/ofid/ofz246. eCollection 2019 Jun.

7.

Inhibition of HIV Maturation via Selective Unfolding and Cross-Linking of Gag Polyprotein by a Mercaptobenzamide Acetylator.

Miller Jenkins LM, Paine EL, Deshmukh L, Nikolayevskiy H, Lyons GC, Scerba MT, George Rosenker K, Luecke HF, Louis JM, Chertova E, Gorelick RJ, Ott DE, Clore GM, Appella DH.

J Am Chem Soc. 2019 May 22;141(20):8327-8338. doi: 10.1021/jacs.9b02743. Epub 2019 May 13.

PMID:
31042030
8.

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.

Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, Benjapornpong K, Tangnaree K, Chomchey N, Kroon E, de Souza MS, Tovanabutra S, Rolland M, Eller MA, Paquin-Proulx D, Bolton DL, Tokarev A, Thomas R, Takata H, Trautmann L, Krebs SJ, Modjarrad K, McDermott AB, Bailer RT, Doria-Rose N, Patel B, Gorelick RJ, Fullmer BA, Schuetz A, Grandin PV, O'Connell RJ, Ledgerwood JE, Graham BS, Tressler R, Mascola JR, Chomont N, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV397 Study Group.

Lancet HIV. 2019 May;6(5):e297-e306. doi: 10.1016/S2352-3018(19)30053-0. Epub 2019 Apr 15.

PMID:
31000477
9.

Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial.

Lee SA, Elliott JH, McMahon J, Hartogenesis W, Bumpus NN, Lifson JD, Gorelick RJ, Bacchetti P, Deeks SG, Lewin SR, Savic RM.

Clin Pharmacol Ther. 2019 Mar;105(3):692-702. doi: 10.1002/cpt.1220. Epub 2018 Oct 9.

10.

Modulation of the HIV nucleocapsid dynamics finely tunes its RNA-binding properties during virion genesis.

Mouhand A, Belfetmi A, Catala M, Larue V, Zargarian L, Brachet F, Gorelick RJ, Van Heijenoort C, Mirambeau G, Barraud P, Mauffret O, Tisné C.

Nucleic Acids Res. 2018 Oct 12;46(18):9699-9710. doi: 10.1093/nar/gky612.

11.

Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection.

Colby DJ, Trautmann L, Pinyakorn S, Leyre L, Pagliuzza A, Kroon E, Rolland M, Takata H, Buranapraditkun S, Intasan J, Chomchey N, Muir R, Haddad EK, Tovanabutra S, Ubolyam S, Bolton DL, Fullmer BA, Gorelick RJ, Fox L, Crowell TA, Trichavaroj R, O'Connell R, Chomont N, Kim JH, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV411 study group.

Nat Med. 2018 Jul;24(7):923-926. doi: 10.1038/s41591-018-0026-6. Epub 2018 Jun 11.

12.

Ultrasensitive Immunoassay for Simian Immunodeficiency Virus p27CA.

Swanstrom AE, Gorelick RJ, Wu G, Howell B, Vijayagopalan A, Shoemaker R, Oswald K, Datta SA, Keele BF, Del Prete GQ, Chertova E, Bess JW Jr, Lifson JD.

AIDS Res Hum Retroviruses. 2018 Nov;34(11):993-1001. doi: 10.1089/AID.2018.0075. Epub 2018 Jul 10.

13.

Mechanistic differences between HIV-1 and SIV nucleocapsid proteins and cross-species HIV-1 genomic RNA recognition.

Post K, Olson ED, Naufer MN, Gorelick RJ, Rouzina I, Williams MC, Musier-Forsyth K, Levin JG.

Retrovirology. 2016 Dec 29;13(1):89. doi: 10.1186/s12977-016-0322-5.

14.

Minimal Contribution of APOBEC3-Induced G-to-A Hypermutation to HIV-1 Recombination and Genetic Variation.

Delviks-Frankenberry KA, Nikolaitchik OA, Burdick RC, Gorelick RJ, Keele BF, Hu WS, Pathak VK.

PLoS Pathog. 2016 May 17;12(5):e1005646. doi: 10.1371/journal.ppat.1005646. eCollection 2016 May.

15.

Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC.

Nature. 2016 Jul 28;535(7613):580. doi: 10.1038/nature17642. Epub 2016 Mar 23. No abstract available.

PMID:
27007847
16.

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.

Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, Enama ME, Plummer S, Holman L, Hendel CS, Gordon I, Casazza J, Conan-Cibotti M, Migueles SA, Tressler R, Bailer RT, McDermott A, Narpala S, O'Dell S, Wolf G, Lifson JD, Freemire BA, Gorelick RJ, Pandey JP, Mohan S, Chomont N, Fromentin R, Chun TW, Fauci AS, Schwartz RM, Koup RA, Douek DC, Hu Z, Capparelli E, Graham BS, Mascola JR, Ledgerwood JE; VRC 601 Study Team.

Sci Transl Med. 2015 Dec 23;7(319):319ra206. doi: 10.1126/scitranslmed.aad5752.

PMID:
26702094
17.

Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study.

Elliott JH, McMahon JH, Chang CC, Lee SA, Hartogensis W, Bumpus N, Savic R, Roney J, Hoh R, Solomon A, Piatak M, Gorelick RJ, Lifson J, Bacchetti P, Deeks SG, Lewin SR.

Lancet HIV. 2015 Dec;2(12):e520-9. doi: 10.1016/S2352-3018(15)00226-X. Epub 2015 Nov 17.

18.

Targeted binding of nucleocapsid protein transforms the folding landscape of HIV-1 TAR RNA.

McCauley MJ, Rouzina I, Manthei KA, Gorelick RJ, Musier-Forsyth K, Williams MC.

Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):13555-60. doi: 10.1073/pnas.1510100112. Epub 2015 Oct 19.

19.

Distribution and Redistribution of HIV-1 Nucleocapsid Protein in Immature, Mature, and Integrase-Inhibited Virions: a Role for Integrase in Maturation.

Fontana J, Jurado KA, Cheng N, Ly NL, Fuchs JR, Gorelick RJ, Engelman AN, Steven AC.

J Virol. 2015 Oct;89(19):9765-80. doi: 10.1128/JVI.01522-15. Epub 2015 Jul 15.

20.

Structure-Based Alignment and Consensus Secondary Structures for Three HIV-Related RNA Genomes.

Lavender CA, Gorelick RJ, Weeks KM.

PLoS Comput Biol. 2015 May 20;11(5):e1004230. doi: 10.1371/journal.pcbi.1004230. eCollection 2015 May.

21.

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC.

Nature. 2015 Jun 25;522(7557):487-91. doi: 10.1038/nature14411. Epub 2015 Apr 8. Erratum in: Nature. 2016 Jul 28;535(7613):580.

22.

Sequence and structural determinants of human APOBEC3H deaminase and anti-HIV-1 activities.

Mitra M, Singer D, Mano Y, Hritz J, Nam G, Gorelick RJ, Byeon IJ, Gronenborn AM, Iwatani Y, Levin JG.

Retrovirology. 2015 Jan 22;12:3. doi: 10.1186/s12977-014-0130-8.

23.

Selection of fully processed HIV-1 nucleocapsid protein is required for optimal nucleic acid chaperone activity in reverse transcription.

Wu T, Gorelick RJ, Levin JG.

Virus Res. 2014 Nov 26;193:52-64. doi: 10.1016/j.virusres.2014.06.004. Epub 2014 Jun 20.

24.

Structure and dynamics of the HIV-1 frameshift element RNA.

Low JT, Garcia-Miranda P, Mouzakis KD, Gorelick RJ, Butcher SE, Weeks KM.

Biochemistry. 2014 Jul 8;53(26):4282-91. doi: 10.1021/bi5004926. Epub 2014 Jun 27.

25.

Single aromatic residue location alters nucleic acid binding and chaperone function of FIV nucleocapsid protein.

Wu H, Wang W, Naiyer N, Fichtenbaum E, Qualley DF, McCauley MJ, Gorelick RJ, Rouzina I, Musier-Forsyth K, Williams MC.

Virus Res. 2014 Nov 26;193:39-51. doi: 10.1016/j.virusres.2014.06.002. Epub 2014 Jun 7.

26.

Distinct nucleic acid interaction properties of HIV-1 nucleocapsid protein precursor NCp15 explain reduced viral infectivity.

Wang W, Naiyer N, Mitra M, Li J, Williams MC, Rouzina I, Gorelick RJ, Wu Z, Musier-Forsyth K.

Nucleic Acids Res. 2014 Jun;42(11):7145-59. doi: 10.1093/nar/gku335. Epub 2014 May 9.

27.

An immature retroviral RNA genome resembles a kinetically trapped intermediate state.

Grohman JK, Gorelick RJ, Kottegoda S, Allbritton NL, Rein A, Weeks KM.

J Virol. 2014 Jun;88(11):6061-8. doi: 10.1128/JVI.03277-13. Epub 2014 Mar 12.

28.

Differential contribution of basic residues to HIV-1 nucleocapsid protein's nucleic acid chaperone function and retroviral replication.

Wu H, Mitra M, Naufer MN, McCauley MJ, Gorelick RJ, Rouzina I, Musier-Forsyth K, Williams MC.

Nucleic Acids Res. 2014 Feb;42(4):2525-37. doi: 10.1093/nar/gkt1227. Epub 2013 Nov 28.

29.

Retrovirus-specific differences in matrix and nucleocapsid protein-nucleic acid interactions: implications for genomic RNA packaging.

Sun M, Grigsby IF, Gorelick RJ, Mansky LM, Musier-Forsyth K.

J Virol. 2014 Jan;88(2):1271-80. doi: 10.1128/JVI.02151-13. Epub 2013 Nov 13.

30.

HIV-1 nucleocapsid proteins as molecular chaperones for tetramolecular antiparallel G-quadruplex formation.

Rajendran A, Endo M, Hidaka K, Tran PL, Mergny JL, Gorelick RJ, Sugiyama H.

J Am Chem Soc. 2013 Dec 11;135(49):18575-85. doi: 10.1021/ja409085j. Epub 2013 Nov 27.

31.

Comparison of SIV and HIV-1 genomic RNA structures reveals impact of sequence evolution on conserved and non-conserved structural motifs.

Pollom E, Dang KK, Potter EL, Gorelick RJ, Burch CL, Weeks KM, Swanstrom R.

PLoS Pathog. 2013;9(4):e1003294. doi: 10.1371/journal.ppat.1003294. Epub 2013 Apr 4.

32.

Dimeric RNA recognition regulates HIV-1 genome packaging.

Nikolaitchik OA, Dilley KA, Fu W, Gorelick RJ, Tai SH, Soheilian F, Ptak RG, Nagashima K, Pathak VK, Hu WS.

PLoS Pathog. 2013 Mar;9(3):e1003249. doi: 10.1371/journal.ppat.1003249. Epub 2013 Mar 21.

33.

A guanosine-centric mechanism for RNA chaperone function.

Grohman JK, Gorelick RJ, Lickwar CR, Lieb JD, Bower BD, Znosko BM, Weeks KM.

Science. 2013 Apr 12;340(6129):190-5. doi: 10.1126/science.1230715. Epub 2013 Mar 7.

34.

Structural basis for high-affinity binding of LEDGF PWWP to mononucleosomes.

Eidahl JO, Crowe BL, North JA, McKee CJ, Shkriabai N, Feng L, Plumb M, Graham RL, Gorelick RJ, Hess S, Poirier MG, Foster MP, Kvaratskhelia M.

Nucleic Acids Res. 2013 Apr 1;41(6):3924-36. doi: 10.1093/nar/gkt074. Epub 2013 Feb 8.

35.

Molecular determinants of HIV-1 NCp7 chaperone activity in maturation of the HIV-1 dimerization initiation site.

Aduri R, Briggs KT, Gorelick RJ, Marino JP.

Nucleic Acids Res. 2013 Feb 1;41(4):2565-80. doi: 10.1093/nar/gks1350. Epub 2012 Dec 28.

36.

Zinc finger function of HIV-1 nucleocapsid protein is required for removal of 5'-terminal genomic RNA fragments: a paradigm for RNA removal reactions in HIV-1 reverse transcription.

Hergott CB, Mitra M, Guo J, Wu T, Miller JT, Iwatani Y, Gorelick RJ, Levin JG.

Virus Res. 2013 Feb;171(2):346-55. doi: 10.1016/j.virusres.2012.08.013. Epub 2012 Nov 10.

37.

A protein ballet around the viral genome orchestrated by HIV-1 reverse transcriptase leads to an architectural switch: from nucleocapsid-condensed RNA to Vpr-bridged DNA.

Lyonnais S, Gorelick RJ, Heniche-Boukhalfa F, Bouaziz S, Parissi V, Mouscadet JF, Restle T, Gatell JM, Le Cam E, Mirambeau G.

Virus Res. 2013 Feb;171(2):287-303. doi: 10.1016/j.virusres.2012.09.008. Epub 2012 Sep 24.

38.

Aromatic residue mutations reveal direct correlation between HIV-1 nucleocapsid protein's nucleic acid chaperone activity and retroviral replication.

Wu H, Mitra M, McCauley MJ, Thomas JA, Rouzina I, Musier-Forsyth K, Williams MC, Gorelick RJ.

Virus Res. 2013 Feb;171(2):263-77. doi: 10.1016/j.virusres.2012.07.008. Epub 2012 Jul 16.

39.

Studies on the restriction of murine leukemia viruses by mouse APOBEC3.

Sanchez-Martinez S, Aloia AL, Harvin D, Mirro J, Gorelick RJ, Jern P, Coffin JM, Rein A.

PLoS One. 2012;7(5):e38190. doi: 10.1371/journal.pone.0038190. Epub 2012 May 29.

40.

Genomic HIV RNA induces innate immune responses through RIG-I-dependent sensing of secondary-structured RNA.

Berg RK, Melchjorsen J, Rintahaka J, Diget E, Søby S, Horan KA, Gorelick RJ, Matikainen S, Larsen CS, Ostergaard L, Paludan SR, Mogensen TH.

PLoS One. 2012;7(1):e29291. doi: 10.1371/journal.pone.0029291. Epub 2012 Jan 3.

41.

Femtomole SHAPE reveals regulatory structures in the authentic XMRV RNA genome.

Grohman JK, Kottegoda S, Gorelick RJ, Allbritton NL, Weeks KM.

J Am Chem Soc. 2011 Dec 21;133(50):20326-34. doi: 10.1021/ja2070945. Epub 2011 Nov 29.

42.

The interdomain linker region of HIV-1 capsid protein is a critical determinant of proper core assembly and stability.

Jiang J, Ablan SD, Derebail S, Hercík K, Soheilian F, Thomas JA, Tang S, Hewlett I, Nagashima K, Gorelick RJ, Freed EO, Levin JG.

Virology. 2011 Dec 20;421(2):253-65. doi: 10.1016/j.virol.2011.09.012. Epub 2011 Oct 26.

43.

HIV-1 nucleocapsid protein increases strand transfer recombination by promoting dimeric G-quartet formation.

Shen W, Gorelick RJ, Bambara RA.

J Biol Chem. 2011 Aug 26;286(34):29838-47. doi: 10.1074/jbc.M111.262352. Epub 2011 Jul 7.

44.

Blocking premature reverse transcription fails to rescue the HIV-1 nucleocapsid-mutant replication defect.

Thomas JA, Shatzer TL, Gorelick RJ.

Retrovirology. 2011 Jun 17;8:46. doi: 10.1186/1742-4690-8-46.

45.

Features, processing states, and heterologous protein interactions in the modulation of the retroviral nucleocapsid protein function.

Mirambeau G, Lyonnais S, Gorelick RJ.

RNA Biol. 2010 Nov-Dec;7(6):724-34. Epub 2010 Nov 1. Review.

46.

TCR triggering transcriptionally downregulates CCR5 expression on rhesus macaque CD4(+) T-cells with no measurable effect on susceptibility to SIV infection.

Minang JT, Trivett MT, Barsov EV, Del Prete GQ, Trubey CM, Thomas JA, Gorelick RJ, Piatak M Jr, Ott DE, Ohlen C.

Virology. 2011 Jan 5;409(1):132-40. doi: 10.1016/j.virol.2010.10.005. Epub 2010 Oct 28.

47.

Definition of a high-affinity Gag recognition structure mediating packaging of a retroviral RNA genome.

Gherghe C, Lombo T, Leonard CW, Datta SA, Bess JW Jr, Gorelick RJ, Rein A, Weeks KM.

Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19248-53. doi: 10.1073/pnas.1006897107. Epub 2010 Oct 25.

48.

Fundamental differences between the nucleic acid chaperone activities of HIV-1 nucleocapsid protein and Gag or Gag-derived proteins: biological implications.

Wu T, Datta SA, Mitra M, Gorelick RJ, Rein A, Levin JG.

Virology. 2010 Sep 30;405(2):556-67. doi: 10.1016/j.virol.2010.06.042. Epub 2010 Jul 23.

49.

Secondary structure of the mature ex virio Moloney murine leukemia virus genomic RNA dimerization domain.

Gherghe C, Leonard CW, Gorelick RJ, Weeks KM.

J Virol. 2010 Jan;84(2):898-906. doi: 10.1128/JVI.01602-09. Epub 2009 Nov 4.

50.

C-terminal domain modulates the nucleic acid chaperone activity of human T-cell leukemia virus type 1 nucleocapsid protein via an electrostatic mechanism.

Qualley DF, Stewart-Maynard KM, Wang F, Mitra M, Gorelick RJ, Rouzina I, Williams MC, Musier-Forsyth K.

J Biol Chem. 2010 Jan 1;285(1):295-307. doi: 10.1074/jbc.M109.051334. Epub 2009 Nov 3.

Supplemental Content

Loading ...
Support Center